HURA logo

HURA

TuHURA Biosciences, Inc.NASDAQHealthcare
$1.41-12.96%ClosedMarket Cap: $79.6M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

PEG

P/B

3.23

P/S

0.00

EV/EBITDA

0.00

DCF Value

$0.07

FCF Yield

-51.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-179.4%

ROA

-180.9%

ROIC

0.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$0.00$-6.8M$-0.13
FY 2025$0.00$-30.1M$-0.63
Q3 2025$0.00$-7.1M$-0.14
Q2 2025$0.00$-9.5M$-0.21

Analyst Ratings

View All
HC Wainwright & Co.Buy
2026-02-03
Maxim GroupBuy
2025-11-14
HC Wainwright & Co.Buy
2025-05-16

Trading Activity

Insider Trades

View All
Tendler Craigdirector
SellTue Feb 17
Ng George Kdirector
SellTue Feb 17
MANUSO JAMES S Jdirector
SellTue Feb 17
List Alandirector
SellTue Feb 17
Hoffman Robert E.director
SellTue Feb 17

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

-0.31

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Peers